Presenter Profiles for BIO National Venture Conference 2009

BIO National Venture Conference 2009 takes place March 31 – April 1, 2009 at the Sheraton Boston Hotel in Boston.

Business Wire is the official news wire for BIO National Venture Conference 2009. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Listed below are the BIO National Venture Conference 2009 presenter profiles.

Company:	Catena Pharmaceuticals, Inc.
Investor Relations Contact:	Ian Mehr
Investor Relations Contact Phone:	888-265-1353
Web:	www.catenapharma.com
Date of Presentation:	April 1, 2009, 2:25 PM
While therapeutic advances have been made, cancer remains a scourge as the second leading cause of death in the United States, creating intense suffering and major economic costs on the healthcare system. Catena Pharmaceuticals's proprietary technology has demonstrated a unique ability to aggressively fight the growth of cancerous tumors in animal models. Catena's exciting drug platform attacks cancer through a validated drug target class and by a proven mechanism: blocking blood flow to tumors (angiogenesis) and starving them of oxygen. Catena seeks financing to advance its lead anti-cancer drug candidate, VPC51299, towards human clinical trials.
Company:	GliaMed, Inc.
Investor Relations Contact:	Andrew Uprichard, CEO
Investor Relations Contact Phone:	1 (508) 626-0077 x112
Web:	www.GliaMed.com
Date of Presentation:	3/31/09
GliaMed is developing a small molecule approach to stem cell therapy. Founded in 2001, the company is developing Regenerative Immunophilin Ligands (RILs). In preclinical models, RILs have been shown to induce the localized expression of transcription factors characteristic of pluripotent stem cells at the site of acute disease or trauma. These cells can then be reprogrammed by local signals to become neurons, cardiac myocytes, chondrocytes or other cell types, which then contribute to fully differentiated tissues such as skin. GliaMed's lead candidate, GM1485, has been administered to more than 500 human subjects. The company acquired this compound in 2007.
Company:	Mirna Therapeutics
Investor Relations Contact:	Rollie Carlson
Investor Relations Contact Phone:	512-681-5211
Web:	http://www.mirnarx.com/
Date of Presentation:	4/1/09
Mirna Therapeutics, Inc. ("Mirna") is a biopharmaceutical company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to be a major "platform" company in the emerging field of miRNA-based therapeutics. Mirna has developed two miRNA drug candidates that are able to inhibit tumor development and metastasis in multiple mouse models of prostate and lung cancer. Mirna is a spin-off of Asuragen, a miRNA-based diagnostics company. Mirna was founded on miRNA technologies and intellectual property first developed at Ambion, Inc. that date back to 2002.
Company:	NeurAxon
Investor Relations Contact:	Chris Erdman
Investor Relations Contact Phone:	781-235-3060
Web:	www.neuraxon.com
Date of Presentation:	April 1, 2009 10:35-10:50am
NeurAxon is a leader in discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon has generated a proprietary pipeline of five product candidates for the following indications: acute migraine, neuropathic pain, rheumatoid arthritis, migraine prophylaxis and severe pain. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT (5-HT is the mechanism of action of triptans, the largest class of migraine drugs) agonism that is being developed for the treatment of acute migraine.

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.

Business Wire
Global Event Services
310-820-9473
http://www.businesswire.com
http://www.tradeshownews.com

(Source: Business Wire )

China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results

HERCULES, CA and BILLERICA, MA, Mar 23, 2009 (MARKET WIRE via COMTEX) ----Bio-Rad Laboratories, Inc. (NYSE: BIO: 64.93, 0, 0%) and (NYSE: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Bruker Corporation (NASDAQ: BRKR), a leading manufacturer of mass spectrometry (MS: 26.039, n.a., n.a.%) instruments, today announced that they have signed an exclusive partnership agreement to develop and market new products based on Bio-Rad's surface-enhanced laser desorption/ionization (SELDI: undefined, undefined, undefined%) technology in combination with Bruker's matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometers for applications of high-throughput protein profiling and identification. The products will provide new solutions for biomarker discovery, in particular, the detection and high-confidence identification of intact peptides and proteins under 30 kilodaltons, which are known to be challenging for currently available technologies to identify.

"We're confident that Bio-Rad's SELDI technology combined with the flexibility delivered by Bruker's TOF/TOF systems will offer tangible benefits to researchers for protein biomarker discovery," said Brad Crutchfield, Bio-Rad Vice President and Life Science Group Manager. "We welcome the opportunity to work with Bruker, a company that, similar to Bio-Rad, has a long history of advancing life science research through its commitment to customer support."

"We are excited about working with Bio-Rad," said Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics. "Bruker Daltonics' high-performance TOF/TOF technology will bring a new dimension to protein profiling and identification, expanding the capabilities of Bio-Rad's established SELDI technology. New products based on this combination of technologies will allow access to new technical capabilities and new market segments in applied proteomics, enabling researchers to better identify and characterize new biomarkers."

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO: 64.93, 0, 0%) and (NYSE: BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

About Bruker Daltonics

Bruker Daltonics is a leading manufacturer of mass spectrometry (MS: 26.039, n.a., n.a.%) instruments and accessories for life science, pharmaceutical, biochemical and chemical research as well as for applied analytical tasks in forensics and food safety. Technical solutions are based on a comprehensive range of MALDI-TOF/TOF, ESI-Qq-TOF, ESI-ITMS, and ESI/MALDI-FTMS mass spectrometry systems, as well as automated sample handling systems and productivity enhancing software. For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

    For more information, contact:    Bio-Rad Laboratories, Inc.    Tina Cuccia    Corporate Communications Manager    510-724-7000    Email Contact        Bruker Corporation    Stacey Desrochers    Investor Relations    978-663-3660 x 1115    Email Contact            

SOURCE: Bio-Rad Laboratories

 http://www2.marketwire.com/mw/emailprcntct?id=876CC5C8A5A3B1D5    http://www2.marketwire.com/mw/emailprcntct?id=B10855C35E52DEC6    

 Copyright 2009  Market Wire, All rights reserved.

Bio Medica sales down, net loss up in 4Q

American Bio Medica Corp. reported lower sales, and a bigger net loss, for the fourth quarter.

The Kinderhook, N.Y. company, which makes drug-testing kits, had a net loss of $672,000, or 3 cents a share, for the three months ended Dec. 31. This compares to a net loss of $28,000, or less than a penny a share, a year earlier.

Sales for the quarter totaled $2.3 million, down from $3.3 million in the year-ago period.

"Sales in the fourth quarter of 2008 suffered greatly, especially in December of 2008, as a result of the overall condition of the global economy," said Stan Cipkowski, CEO of American Bio Medica. "More specifically, sales in our national account division, which sells primarily to the workplace market and historically sees year over year growth, declined as new and existing employment levels continued to be negatively impacted. In addition, budget cuts and price pressure continue to negatively affect our government sales division. On a brighter note, we have continued to see growth in sales outside of the United States, especially in Latin America."

For all of 2008, American Bio Medica (Nasdaq: ABMC) reported a net loss of $850,000, or 4 cents a share, on sales of $12.6 million. This compares to a loss of $990,000, or 5 cents a share, in 2007.

Cynvec to Present at the BIO National Venture Conference

NEW YORK, March 25, 2009 /PRNewswire via COMTEX/ ----Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will present at the BIO National Venture Conference in Boston on Wednesday, April 1, 2009 at 1:45 p.m. ET.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in ovarian cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.

SOURCE Cynvec LLC

 http://www.cynvec.com    

 Copyright (C: 2.909, n.a., n.a.%) 2009 PR Newswire. All rights reserved

BIO Holds Diversity Summit at 2009 BIO International Convention in Atlanta

WASHINGTON, Mar 25, 2009 (BUSINESS WIRE) ----The Biotechnology Industry Organization (BIO: 64.93, 0, 0%) invites leaders in workforce development, science education, health disparities and community outreach to attend Fulfilling the Promise: Diversity in Biotechnology Summit on Monday, May 18, 2009 from 8:30 a.m. - 5:00 p.m. at the Omni Hotel at CNN Center in Atlanta. Part of the 2009 BIO International Convention, the inaugural event will include discussions with industry representatives, policymakers and community leaders.

"Diversity is important to our industry and this summit will focus on how to encourage more diversity within the workforce," said Robbi Lycett, vice president of Conventions & Conferences at BIO. "We are pleased to bring together individuals from industry, academia, government and the non-profit sector to discuss important topics related to diversity within biotechnology, such as economic and workforce development, health disparities and community outreach, education and access."

Highlights include:

-- Plenary breakfast featuring Atlanta Mayor Shirley Franklin and Georgia Representative John Lewis;

-- Economic/workforce development panel featuring Dr. Michael L. Penn, Jr., Genentech;

-- Legislative roundtable discussing federal and state legislative initiatives moderated by US Delegate Donna Christensen;

-- Health disparities and community outreach panel featuring Dr. Carolyn Britton of the National Medical Association;

-- A town hall meeting on education, access and awareness of the future of technology with Dr. Otis Brawley of the American Cancer Society and Dr. Eve Higginbotham from the Morehouse School of Medicine;

-- As well as keynote addresses from Governor Luis G. Fortuno of Puerto Rico and the Honorable Louis Sullivan.

For additional information or to register for the Diversity in Biotechnology Summit, please contact Julia Moorhead at jmoorhead@bio.org or at 202.962.9509 by Friday, April 17, 2009.

To register for the 2009 BIO International Convention, please visit http://convention.bio.org.

The BIO International Convention helps to support BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation. For more information on the global event for biotechnology, including program and housing information, please visit http://convention.bio.org.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

BIO IP Counsels' Committee Conference March 25-27, 2009 Phoenix, AZ

BIO National Venture Conference March 31-April 1, 2009 Boston, MA

BIO Windhover 2009 April 13-15, 2009 New York, NY

BIO-LES Business Development Basics Course May 15-17, 2009 Atlanta, GA

BIO-LES Advanced Business Development Course May 15-17, 2009 Atlanta, GA

BIO Executive Presentation Workshop May 17, 2009 Atlanta, GA

BIO Human Resources Conference May 17-19, 2009 Atlanta, GA

2009 BIO International Convention May 18-21, 2009 Atlanta, GA

BioEquity Europe June 9-10, 2009 Munich, Germany

World Congress on Industrial Biotechnology & Bioprocessing July 19-22, 2009 Montreal, Quebec, Canada

SOURCE: Biotechnology Industry Organization (BIO: 64.93, 0, 0%)

    Biotechnology Industry Organization (BIO: 64.93, 0, 0%)     Tracy Krughoff, 202-312-9274     tkrughoff@bio.org    

 Copyright Business Wire 2009